SCOPUS 정보 검색 플랫폼

European Journal of Cancer

Volumn 37, Issue 18, 2001, Pages 2357-2364

Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer

(8) Boucaud, M a,b Pinguet, F a Poujol, S a Romieu, G a Cupissol, D a Astre, C a Culine, S a Bressolle, F a,b

a Anticancer Center (France)

b UNIV MONTPELLIER (France)

Author keywords

Pharmacodynamics; Pharmacokinetics; Plasma; Saliva; Topotecan

Indexed keywords

HYCANTIN; TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SALIVA LEVEL; FEMALE; GRANULOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NEUTROPHIL; OVARY CARCINOMA; PAROTID GLAND; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; SALIVA; TOPOTECAN;

EID: 0035200473 PISSN: 09598049 EISSN: None Source Type: Journal
DOI: 10.1016/S0959-8049(01)00312-4 Document Type: Article

Times cited : (13)

References (29)

1
- 0027292407
- DNA topoisomerase I and II as targets for rational design of new anticancer drugs
- (1993) Ann Oncol , vol.4 , pp. 533-543
- Cummings, J.¹ Smyth, J.F.²

2
- 0027447420
- The current status of camptothecin analogues as antitumor agents
- (1993) J Natl Canc Inst , vol.85 , pp. 271-291
- Slichenmeyer, W.J.¹ Rowinsky, E.K.² Donehower, R.C.³ Kaufmann, S.H.⁴

3
- 0029034767
- High-perfomance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of lactone plus carboxylate forms, in human plasma
- (1995) J Chromatogr B Biomed Appl , vol.668 , pp. 107-115
- Rosing, H.¹ Doyle, E.² Davies, B.E.³ Beijnen, J.H.⁴

4
- 0025597927
- High-performance liquid chromatographic analysis of the new antitumour drug SK and F 104864-A (NSC 609699) in plasma
- (1990) J Pharm Biomed Anal , vol.8 , pp. 789-794
- Beijnen, J.H.¹ Smith, B.R.² Keijer, W.J.³

5
- 0024537205
- Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
- (1989) J Med Chem , vol.32 , pp. 715-720
- Hertzberg, R.P.¹ Caranfa, M.J.² Holden, K.G.³

6
- 0029947777
- Clinical pharmacokinetics of topotecan
- (1996) Clin Pharmacokinet , vol.2 , pp. 85-102
- Herben, V.M.M.¹ Ten Bokkel Huinink, W.W.² Beijnen, J.H.³

7
- 0035002615
- Topoisomerase I inhibition with topotecan: Pharmacologic and clinical issues
- (2001) Expert Opin Pharmacother , vol.2 , pp. 491-505
- Arun, B.¹ Frenkel, E.P.²

8
- 0030913459
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
- The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group
- (1997) J Clin Oncol , vol.15 , pp. 2090-2096
- Ardizzoni, A.¹ Hansen, H.² Dombernowsky, P.³

9
- 0001730741
- A phase II trial of topotecan (TPT) for the treatment of advanced measurable colorectal cancer
- abstr 686
- (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 225
- Sugarman, S.M.¹ Ajani, J.A.² Daugherty, K.³ Winn, R.⁴ Lanzotti, V.⁵ Bearden, J.D.⁶ Abbruzzese, J.L.⁷

10
- 0033450760
- New developments in the treatment of acute myeloid leukemia: Focus on topotecan
- (1999) Semin Hematol , vol.36 , pp. 16-25
- Kantarjian, H.¹

11
- 0035025316
- A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study
- (2001) Gynecol Oncol , vol.81 , pp. 213-215
- Muderspach, L.I.¹ Blessing, J.A.² Levenback, C.³ Moore, J.L.⁴

12
- 0031786482
- Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
- (1998) J Clin Oncol , vol.16 , pp. 3345-3352
- Bookman, M.A.¹ Malmstrom, H.² Bolis, G.³

13
- 0031781459
- Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
- (1998) J Clin Oncol , vol.16 , pp. 2233-2237
- Hoskins, P.¹ Eisenhauer, E.² Beare, S.³

14
- 0032922740
- Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
- (1999) Oncology , vol.56 , pp. 1-12
- Kollmannsberger, C.¹ Mross, K.² Jakob, A.³ Kanz, L.⁴ Bokemeyer, C.⁵

15
- 0025663422
- Equilibrium kinetics of the new experimental anti-tumour compound SK and F 104864-A (NSC 609699) in plasma
- (1990) J Pharm Biomed Anal , vol.8 , pp. 681-683
- Underberg, W.J.M.¹ Goossen, R.M.J.² Smith, B.R.³ Beijnen, J.H.⁴

16
- 0027096415
- A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
- (1992) J Pharm Sci , vol.81 , pp. 676-684
- Fassberg, J.¹ Stella, V.J.²

17
- 0029656180
- Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors
- (1996) Cancer Chemother Pharmacol , vol.37 , pp. 195-202
- Baker, S.D.¹ Heideman, R.L.² Crom, W.R.³ Kuttesch, J.F.⁴ Gajjar, A.⁵ Stewart, C.F.⁶

18
- 0026646768
- Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
- (1992) Drug Metab Dispos , vol.20 , pp. 706-713
- Grochow, L.B.¹ Rowinsky, E.K.² Johnson, R.³

19
- 0028130504
- Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
- (1994) J Clin Oncol , vol.12 , pp. 1946-1954
- Stewart, C.F.¹ Baker, S.D.² Heideman, R.L.³ Jones, D.⁴ Crom, W.R.⁵ Pratt, C.B.⁶

20
- 0028144882
- Clinical, pharmacokinetic and biological studies of topotecan
- (1994) Cancer Chemother Pharmacol , vol.34 , pp. S46-S52
- O'Dweyer, P.J.¹ LaCreta, F.P.² Haas, N.B.³

21
- 0028796513
- Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 week
- (1995) Cancer Chemother Pharmacol , vol.35 , pp. 237-245
- Van Warmerdam, L.J.¹ Verweij, J.² Shellens, J.H.³ Rosing, H.⁴ Davies, B.E.⁵ De Boer-Dennert, M.⁶

22
- 0016916438
- Prediction of creatinine clearance from serum creatinine
- (1976) Nephron , vol.16 , pp. 31-47
- Cockcroft, D.W.¹ Gault, M.H.²

23
- 0033729430
- Population pharmacokinetics of topotecan: Intraindividual variability of total drug
- (2000) Cancer Chemother Pharmacol , vol.46 , pp. 375-381
- Montazeri, A.¹ Boucaud, M.² Lokiec, F.³

24
- 0033804373
- Sensitive high-performance liquid chromatographic fluorescence determination of topotecan in human plasma and parotid saliva
- (2000) J Liq Chrom Rel Technol , vol.23 , pp. 2373-2390
- Boucaud, M.¹ Pinguet, F.² Poujol, S.³ Astre, C.⁴ Bressolle, F.⁵

25
- 0003747347
- San Francisco, USA, University of California at San Francisco
- (1992) NONMEM User's Guide
- Beal, S.L.¹ Sheiner, L.B.²

26
- 0003784334
- Montpellier, France, RDPP
- (1998) Visual-NM User's Manual, Version 5.1

27
- 0003392024
- Montpellier, France, RDPP
- (1999) Pk-fit Computer Program, Version 2.1

28
- 0002339148
- Do topotecan concentrations in saliva reflect plasma concentrations?
- (1995) J Oncol Pharm Practice , vol.1 , pp. 41-45
- Van Warmerdam, L.J.¹ Rosing, H.² Ten Bokkel Huinink, W.W.³ Maes, R.A.A.⁴ Beijnen, J.H.⁵

29
- 0033083155
- Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer undergoing LV5FU2 chemotherapy regimen
- (1999) Eur J Cancer , vol.35 , pp. 296-301
- Joulia, J.M.¹ Pinguet, F.² Ychou, M.³ Duffour, J.⁴ Astre, C.⁵ Bressolle, F.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.